Zacks: Innate Pharma (IPHYF) Receives Average Rating of “Strong Buy” from Analysts
Innate Pharma (NASDAQ:IPHYF) has received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Zacks has also given Innate Pharma an industry rank of 157 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research raised Innate Pharma from a “sell” rating to a “hold” rating in a research note on Tuesday, May 9th.
Shares of Innate Pharma (IPHYF) opened at 12.24 on Friday. The stock has a 50 day moving average of $13.17 and a 200-day moving average of $13.03. The firm has a market capitalization of $660.86 million and a PE ratio of 47.81. Innate Pharma has a 12 month low of $10.72 and a 12 month high of $16.55.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/07/07/zacks-innate-pharma-iphyf-receives-average-rating-of-strong-buy-from-analysts.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.